This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (48)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Pediatric Otolaryngology  • Alert me on articles by topic

Seth M. Pransky, MD; Douglas F. Brewster, MD; Anthony E. Magit, MD; Donald B. Kearns, MD

Arch Otolaryngol Head Neck Surg. 2000;126:1239-1243.

Objectives  To continue assessment of the benefits and risks of intralesional administration of cidofovir, an acyclic nucleoside phosphonate, for treating severe recurrent respiratory papillomatosis (RRP) in pediatric patients, and to discuss guidelines for larger prospective multi-institutional studies of the use of cidofovir.

Design  Prospective case series.

Setting  Tertiary care children's hospital.

Patients  A total of 10 patients with severe RRP (defined as requiring debulking procedures to maintain airway patency at least once a month) underwent intralesional cidofovir therapy. The original 5 patients have received more than 1 year of follow-up since their last cidofovir injection, and 5 subsequent patients have been treated with a revised injection protocol.

Intervention  Microsuspension laryngoscopy with intralesional injection of cidofovir after repetitive carbon dioxide laser treatments and mechanical debulking of papillomas.

Main Outcome Measures  Papilloma stage at the time of serial laryngoscopies. Histologic examination of biopsy specimens of laryngeal tissue obtained 1 year or more after last cidofovir injection.

Results  There was evidence of marked improvement in the 4 of the 5 new patients enrolled under the revised injection protocol, continuation of a disease-free state in 1 of the original 5 patients, and sustained improvement in 4 of the 5 original patients, resulting in a significantly reduced interval of intervention.

Conclusions  Intralesional cidofovir therapy continues to show benefit in the treatment of severe RRP in pediatric patients. Safety profiles have not been fully established, but current histologic data are reassuring.

From the Department of Pediatric Otolaryngology, Children's Hospital, San Diego, Calif.

RELATED ARTICLE

Archives of Otolaryngology–Head & Neck Surgery Reader's Choice: Continuing Medical Education
Arch Otolaryngol Head Neck Surg. 2000;126(10):1281-1282.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Adult Intralesional Cidofovir Therapy for Laryngeal Papilloma: A 10-Year Perspective
Tanna et al.
Arch Otolaryngol Head Neck Surg 2008;134:497-500.
ABSTRACT | FULL TEXT  

Intralesional Cidofovir for Pediatric Recurrent Respiratory Papillomatosis
Mandell et al.
Arch Otolaryngol Head Neck Surg 2004;130:1319-1323.
ABSTRACT | FULL TEXT  

Predictors of Remission in Juvenile-Onset Recurrent Respiratory Papillomatosis
Ruparelia et al.
Arch Otolaryngol Head Neck Surg 2003;129:1275-1278.
ABSTRACT | FULL TEXT  

A Scheduled Protocol for the Treatment of Juvenile Recurrent Respiratory Papillomatosis With Intralesional Cidofovir
Chhetri and Shapiro
Arch Otolaryngol Head Neck Surg 2003;129:1081-1085.
ABSTRACT | FULL TEXT  

Stepped-Dose Protocol of Cidofovir Therapy in Recurrent Respiratory Papillomatosis in Children
Akst et al.
Arch Otolaryngol Head Neck Surg 2003;129:841-846.
ABSTRACT | FULL TEXT  

Can Mumps Vaccine Induce Remission in Recurrent Respiratory Papilloma?
Pashley
Arch Otolaryngol Head Neck Surg 2002;128:783-786.
ABSTRACT | FULL TEXT  

Another Potential Adjuvant Therapy for Recurrent Respiratory Papillomatosis
Lieu and Molter
Arch Otolaryngol Head Neck Surg 2002;128:787-788.
FULL TEXT